Nucleoside reverse transcriptase inhibitors (NRTIs)

Last updated: November 01, 2022

Nucleoside reverse transcriptase inhibitors (NRTIs)

FOR MAY EXAM 4M 03/18

FOR MAY EXAM 4M 03/18

Disorders of fatty acid metabolism: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pyramidal and extrapyramidal tracts
Ascending and descending spinal tracts
Muscle spindles and golgi tendon organs
Somatosensory pathways
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Heparin-induced thrombocytopenia
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Opioid antagonists
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Opioid agonists, mixed agonist-antagonists and partial agonists
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Cardiac conduction system
Cardiac conduction velocity
ECG basics
ECG rate and rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG normal sinus rhythm
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Extrinsic hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Pulseless electrical activity
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Electrolyte disturbances: Pathology review
Postoperative evaluation: Clinical
Mesothelioma
Lung cancer and mesothelioma: Pathology review
Diffuse parenchymal lung disease: Clinical
Lung cancer: Clinical
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Restrictive lung diseases: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Arsenic poisoning
Cyanide poisoning
Lead poisoning
Methemoglobinemia
Ethylene glycol poisoning
Mercury poisoning
Paracetamol toxicity
Serotonin syndrome
Neuroleptic malignant syndrome
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Pneumothorax
Pneumothorax: Clinical
Chest trauma: Clinical
Pleural effusion: Clinical
Ehlers-Danlos syndrome
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Mediastinum
Shock: Clinical

Transcript

Watch video only

Reverse transcriptase inhibitors are an important part of HAART, or highly active antiretroviral therapy, which is the combination of medications used in the treatment of AIDS.

AIDS is caused by a RNA containing retrovirus called human immunodeficiency virus, or HIV.

The “retro” part of retrovirus isn’t referring to its style, but refers to it needing to use an enzyme called reverse transcriptase to transcribe a piece of “proviral” DNA from its RNA.

As the name suggests, reverse transcriptase inhibitors go and inhibit this enzyme, and prevent HIV replication.

Based on their structure, they can be classified into nucleoside reverse transcriptase inhibitors, or NRTIs; and non-nucleoside reverse transcriptase inhibitors, or NNRTIs.

NRTIs resemble nucleosides, which are tiny molecules which when attached to a phosphate group give rise to nucleotides, which are building blocks of nucleic acids like DNA and RNA.

HIV is a single-stranded, positive-sense, enveloped RNA retrovirus that targets cells in the immune system that have a molecule called CD4 on their membrane.

These include macrophages, dendritic cells, and especially CD4+ T-helper cells.

Normally, the CD4 molecule helps these cells attach to and communicate with other immune cells, which is particularly important when the cells are launching attacks against foreign pathogens.

HIV attaches to the CD4 molecule via a protein called gp120 found on its envelope.

Now, inside its envelope, HIV contains a nucleocapsid which is a capsule containing a single-stranded RNA and some viral enzymes, like reverse transcriptase and integrase.

As HIV bind to the receptors, the viral envelope fuses with the cell membrane of the immune cell, releasing the contents of the nucleocapsid into the helpless host cell’s cytoplasm.

Once it’s inside the CD4+ cell, reverse transcriptase gets to work immediately.

It uses the single stranded viral RNA as a template, and uses the nucleotides present in the cytoplasm of the CD4+ cell to transcribe a complementary double-stranded “proviral” DNA.

Proviral just means that it’s ready to be integrated into the host’s DNA, so it enters the T-helper cell’s nucleus and pops itself into the cell’s DNA, ready to be transcribed into new viruses, pretty sneaky, huh?

Well here’s the actual sneaky part—when the immune cells become activated, they start transcribing and translating proteins needed for the immune response.

Ironically, this means that whenever the immune cell is exposed to something that causes it to start up an immune response, like any infection, the immune cell ends up inadvertently transcribing and translating new HIV viruses, which bud off from the cell membrane to infect more cells. Very sneaky indeed!

Over time, more and more immune cells are infected, and the immune system begins to fail which is called immunodeficiency, and this increases the risk of infections and tumors that a healthy immune system would usually be able to fend off.

These complications are referred to as AIDS, or acquired immunodeficiency syndrome.

NRTIs are structural analogues of nucleosides.

So, when an NRTI molecule enters the cell, it gets phosphorylated, or a phosphate group is added, and it will resemble a nucleotide.

This fake nucleotide molecule now competes with the natural nucleotide in the infected cell for the attention of reverse transcriptase.

If it’s picked and inserted into the proviral DNA, it will screw up HIV’s entire plan.

Think of DNA like a written instruction for synthesizing proteins, and the nucleotides are the letters.

The NRTI molecule are like random foreign letters that disrupts the instruction so viral proteins can’t be made.

Also, additional nucleotides can not be added to the NRTI molecules inserted into the proDNA so this stops its synthesis.

So instead of the proviral DNA, what we end up with are a bunch of incomplete instructions full of gibberish.

This stops new viruses from being created and keeps other CD4+ cells from getting infected.

Key Takeaways

Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of antiviral drugs used to manage HIV infection, which work by inhibiting HIV's reverse transcriptase enzyme. This enzyme prevents the multiplication of the virus and slows down the progression of the disease. Medications in this class include zidovudine, stavudine, lamivudine, didanosine, and tenofovir. Common side effects may include gastrointestinal disturbances like nausea, vomiting, abdominal pain, insomnia, and headache.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "A Review of the Toxicity of HIV Medications" Journal of Medical Toxicology (2013)
  5. "Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus" PLOS ONE (2016)